Tesamorelin
A stabilised GHRH analogue with an FDA approval for HIV-associated lipodystrophy, the only growth-hormone-axis secretagogue with a genuine regulatory signal. Famous for selectively shrinking visceral fat.
Choose an option
- Pay with Bitcoin
- Discreet shipping within Germany
- Purity-guaranteed batches
- 14-day refund period if unsatisfied
Delivery & guarantee
Orders typically arrive within 3 weeks.
If your delivery arrives late, you'll receive a discount on your next order.
About
Tesamorelin is the unicorn of the GH-axis family: a peptide with completed phase-3 trials, an FDA approval (as Egrifta, in 2010), and a defensible mechanism for one of the harder body-composition problems, visceral fat. In two pivotal 26-week trials in HIV-associated lipodystrophy, daily 2 mg subcutaneous injections produced 15 to 20% reductions in visceral adipose tissue without meaningful effect on subcutaneous fat.
Read the full research guideWhy people choose it
- Selective visceral-fat reduction backed by phase-3 data. Not just anecdotal body recomp
- Improved triglycerides and lipid markers as a secondary effect of the visceral-fat loss
- Better sleep quality from the elevated nocturnal GH/IGF-1 pulse
- FDA-approved for a defined indication, so safety pharmacology is well characterised
At a glance
- Experience level
- Intermediate
- Administration
- Subcutaneous
Sold for laboratory research only. Not for human consumption. No therapeutic claims are made.
Sign in to view this product
Tesamorelin
Log in or create a free account to see full details and prices.
Don't have an account? Sign up